Onderneming Celladon Corp Nasdaq
Aandelen
US15117E1073
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 13 | 100,0 % | 16 | 100,0 % | +16,98% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States, Ireland and United Kingdom
100,0
%
| 13 | 100,0 % | 16 | 100,0 % | +16,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Chief Tech/Sci/R&D Officer | 57 | 18-04-22 | |
General Counsel | - | 01-04-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Amit Sachdev
BRD | Director/Board Member | 56 | 15-04-19 |
Evan Loh
BRD | Director/Board Member | 65 | 18-09-17 |
Kim Sablich
BRD | Director/Board Member | 55 | 23-04-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 480 797 | 1 262 028 ( 85,23 %) | 0 | 85,23 % |
Bedrijfsgegevens
Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
94306-1543, Palo Alto
+650 272 6138
http://www.eigerbio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,77% | 49,46 mld. | |
+1,00% | 42,58 mld. | |
+49,96% | 42,49 mld. | |
-5,26% | 29,09 mld. | |
+13,68% | 26,61 mld. | |
-22,99% | 18,64 mld. | |
+8,22% | 13,16 mld. | |
+32,41% | 12,55 mld. | |
+24,01% | 12,1 mld. |